Bibliographic Details
| Title: |
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer |
| Authors: |
Emiliano Calvo, Alexander Spira, María de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, Philippe A. Cassier, Kiyotaka Yoh, Antoine Italiano, Victor Moreno, Katriina Peltola, Takashi Seto, Ryo Toyozawa, Daniel E. Afar, Stefan Englert, Philip Komarnitsky, Stacie Lambert, Apurvasena Parikh, Gregory Vosganian, Bo Gao |
| Source: |
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100405- (2021) |
| Publisher Information: |
Elsevier, 2021. |
| Publication Year: |
2021 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Lung cancer, Immunotherapy, Small-molecule agent, Clinical trial, Antibody-drug conjugate, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Background: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced antitumor activity. Herein, we report results from the expansion arm of study NCT03000257 evaluating the combination of the anti–PD-1 antibody budigalimab and the targeted antibody-drug conjugate rovalpituzumab tesirine (Rova-T) in patients with previously treated SCLC. Materials and methods: This expansion arm of a multicenter, open-label, multi-arm, first-in-human phase 1 clinical trial enrolled adult patients with progressive SCLC. The primary objective was to assess safety and tolerability. Patients received budigalimab 375 mg via intravenous infusion every 3 weeks, and Rova-T was administered as a dose of 0.3 mg/kg intravenously, on day 1 of the first and third 3-week cycle. Results: As of October 2019, 31 patients with SCLC were enrolled and treated with budigalimab plus Rova-T. The combination was tolerated, with the most common treatment-emergent adverse events (in >30%) being pleural effusion, fatigue, and cough. The overall response rate was 24.1%, with one confirmed complete response and six confirmed partial responses. The overall response rate in patients with high delta-like protein 3 expression was similar (21.1%). The median progression-free survival was 3.48 months. Conclusion: Combination therapy with budigalimab and Rova-T had promising efficacy and appeared to be tolerated in patients with SCLC. Although Rova-T development has been discontinued, development of budigalimab combined with other anticancer agents is ongoing. Clinical trial registration number: NCT03000257Statement on originality of the workThe manuscript represents original work and has not been submitted for publication elsewhere nor previously published.Statement of prior presentationData from this study were previously presented at the European Society for Medical Oncology (ESMO) Congress 2019. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2468-2942 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2468294221001039; https://doaj.org/toc/2468-2942 |
| DOI: |
10.1016/j.ctarc.2021.100405 |
| Access URL: |
https://doaj.org/article/e1966145ff134f7d8b7360173186cc8e |
| Accession Number: |
edsdoj.1966145ff134f7d8b7360173186cc8e |
| Database: |
Directory of Open Access Journals |
